तुलना करने के लिए मीट्रिक्स | 3681 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध3681पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −12.0x | −13.3x | −0.4x | |
PEG अनुपात | −0.25 | 0.06 | 0.00 | |
क़ीमत/बुक | 2.5x | 3.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 10.3x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 50.7% | 57.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.0% | 8.9% | अनलॉक करें |
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer’s disease and sjogren’s syndrome. It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as in preclinical trial to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optica spectrum disorder, and multiple sclerosis, as well as in phase 1 clinical trial to treat systemic lupus erythematosus. In addition, the company is developing SM06, a humanised Anti-CD22, that is in preclinical trial to treat systemic lupus erythematosus, rheumatoid arthritis, neuromyelitis optica spectrum disorder, and sjogren’s syndrome; and SM09, a humanised Anti-CD22, which is in preclinical trial to treat non-hodgkin’s lymphoma and autoimmune diseases. Further, it develops Anti-CGC antibody, which is in preclinical trial to treat vitiligo and alopecia areata; and Bispecific antibody candidate (bsAb), which is in preclinical trial to treat osteoporosis. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Tai Po, Hong Kong.